3 results
Approved WMORecruiting
The SPYRAL AFFIRM study will evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in a population of approximately 1300 renal denervation treated subjects with up to 36 months of follow-up, including several sub-…
Approved WMOCompleted
To compare overall survival (OS) of patients with metastatic (Stage IV) PDAC treated with BBI-608 plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine.
Approved WMOCompleted
Primary objective of the study:* To compare overall survival (OS) in the General Population patients treated with BBI-608 plus biweekly FOLFIRI (Arm 1) versus biweekly FOLFIRI (Arm 2)* To compare OS in the pSTAT3-positive (pSTAT3(+)) Subpopulation…